Published in:
Open Access 01-01-2011 | Original Article
A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome
Published in: Sleep and Breathing | Issue 1/2011
Login to get accessAbstract
Purpose
Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome (OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation (SaO2), and sleep architecture were investigated in OSAS patients.
Methods
OSAS patients (n = 48) received 2-week SXB or placebo (PBO) treatment with polysomnography at baseline and day 14. The primary outcome measure was change from baseline in mean AHI. Secondary outcomes included changes from baseline in SaO2, and sleep architecture.
Results
Compared with PBO, SXB significantly increased reduction in mean AHI and obstructive apnea index with SXB (−0.8 ± 13.3 vs. −8.2 ± 10.0; p = 0.0327 and 3.54 ± 11.1 vs. −4.72 ± 7.7; p = 0.0054, respectively) and significantly increased change in slow wave sleep duration (5.2 ± 25.0 min vs. 29.4 ± 37.0 min; p = 0.0038). There were no differences between treatments in SaO2, central apneic events, or other measures. Adverse events, most commonly headache, were noted in nine of 27 (33%) and six of 23 (26%) patients receiving SXB and PBO, respectively.
Conclusions
Short-term use of 4.5 g/night SXB did not generate respiratory depressant effects in OSAS patients as measured by AHI, obstructive apnea events, central apneas, and SaO2. Extended use of SXB in higher therapeutic doses in OSAS has not been studied, and merits caution.